BackgroundSuccessful management of chronic total occlusion (CTO)by percutaneous coronary intervention (PCI) is known to be associated with better clinical outcomes than failed PCI. However, whether angiographic and clinical outcomes following PCI for long CTO lesions differ from those following PCI for short CTO lesions in the drug eluting stent (DES) era remains unknown. We therefore investigated whether CTO lesion length can significantly influence6-month angiographic and 2-year clinical outcomes following successful CTO PCI.Methods and resultsA total of 235 consecutive patients who underwent successful CTO intervention were allocated into either the long or short CTO group according to CTO lesion length. Six-month angiographic and 2-year clinical outcomes were then compared between the 2groups. We found that baseline clinical characteristics were generally similar between the 2 groups. Exceptions were prior PCI, which was more frequent in the long CTO group, and bifurcation lesions, which were more frequent in the short CTO group. Apart from intimal dissection, which was more frequent in the long than short CTO group, in-hospital complications were also similarly frequent between the 2groups. Furthermore, both groups had similar angiographic outcomes at 6 months and clinical outcomes at 2 years. However, the incidence of repeat PCI(predominantly target vessel revascularization),was higher in the long than short CTO group, with our multivariate analysis identifying long CTO as an important predictor of repeat PCI (odds ratio, 4.26;95% confidence interval, 1.53–11.9; p = 0.006).ConclusionThe safety profile, 6-month angiographic, and 2-year clinical outcomes of CTO PCI were similar between patients with long and short CTO. However, there was a higher incidence of repeat PCI in long CTO patients despite successful PCI with DESs.
In our study, there was no relationship between the elevated Lp(a) level and the vasospastic response to the intracoronary ACh provocation test; however, higher Lp(a) levels were associated with poor clinical outcomes up to 5 years.
Background: Chronic total occlusion intervention remains challenging and detailed real-world data on the safety and efficacy of which are limited. This study sought to determine whether there are differences in the 1-year clinical outcomes between chronic total occlusion patients with acute coronary syndrome and stable angina following chronic total occlusion intervention. Patients and methods: Data from the Korean chronic total occlusion registry were collected from May 2003 to September 2012, and a total of 3268 patients who underwent chronic total occlusion intervention were enrolled. Cardiovascular outcomes up to 12 months in the acute coronary syndrome group were compared with stable angina group. Results: The acute coronary syndrome group consisted of 1657 patients, and stable angina group consisted of 1264 patients. In the acute coronary syndrome group, patients with successful chronic total occlusion intervention had a lower incidence of total death and cardiac death compared to patients with failed intervention. However, there were no significant differences in cardiovascular events in the stable angina group. The successful chronic total occlusion intervention was a significant prognostic factor for lower total death (P = 0.006, hazard ratio = 0.46) and cardiac death (P = 0.003, hazard ratio = 0.36) within acute coronary syndrome group. On the other hand, successful chronic total occlusion intervention was not a prognostic factor for cardiovascular events within stable angina group. Conclusions: Successful chronic total occlusion intervention in acute coronary syndrome patients was associated with a lower incidence of cardiovascular outcome compared to patients with failed chronic total occlusion intervention.
Background Bifurcation coronary artery disease (CAD) represents 15-20% in PCI patients, however, limited data concerning the short and long term clinical outcome in AMI. Methods A total of 1402 patients underwent bifurcation lesions PCI were enrolled. Patients were divided into two groups: 1) chronic stable angina group (CSA, N = 954) and 2) acute myocardial infarction group (AMI, N = 448) (241 NSTEMI and 207 STEMI). Major adverse cardiac events (MACE), the composite of death, myocardial infarction (MI), stroke and revascularization and stent thrombosis were compared between the two groups at up to 5 years. Results At 30 days follow up, the AMI group had significantly higher incidence of total death (HR: 5.901, 95% CI : 1.879 to 18.532; p = 0.002), cardiac death (HR: 6.438, 95% CI 1.743 to 23.781; p = 0.005), MI (HR: 4.736 , 95% CI :1.646 to 13.632; p = 0.004), TLR (HR: 4.300 , 95% CI :1.295 to 14.279; p = 0.017), Stroke (HR: 5.901 , 95% CI :1.879 to 18.532; p = 0.002) and MACE (HR: 4.318, 95% CI : 1.940 to 9.611; p = 0.000) than the CSA group moreover, at 5 years follow up the AMI group had significantly higher incidence of MI , TLR , Stent Thrombosis and MACE than the CSA group.Using Multivariate logistic regression, and after adjusting for potential confounding factors, the AMI patients had higher incidence of total MACE at 30 days (HR: 3.668, 95% CI 1.572 to 8.558 ; p = 0.003) and at 5 years MACE (HR: 1.693, 95% CI 1.206 to 2.377 ; p = 0.002) Conclusion In this study, bifurcation lesion PCI in AMI setting was associated with a higher incidence of adverse clinical outcomes at 30 days and up to 5 years. Clinical Outcomes at 5 Years The incidence of Event (%) at 5 years Outcomes CSA (n = 954) AMI(n = 448) Log Rank Hazard ratio (95% Confidence interval ) P value Total death 21 (2.2) 14 (3.1) 0.285 1.443 (0.734-2838) 0.288 Cardiac death 10 (1.0) 10 (2.2) 0.078 2.160 (0.899-5.190) 0.085 Myocardial infarction 22 (2.3) 23 (5.1) 0.004 2.302 (1.283-4.130) 0.005 Revascularization 65 (6.8) 50 (11.2) 0.003 1.749 (1.210-2.529) 0.003 Target lesion 36 (3.7) 45 (6.4) 0.000 2.854 (1.831-4.448) 0.000 Target vessel 42 (4.4) 47 (10.5) 0.000 2.548 (1.680-3.863) 0.000 Non-target vessel 26 (2.7) 8 (1.8) 0.320 0.671 (0.304-1.482) 0.324 Stroke 131 (13.7) 66 (14.7) 0.555 1.093 (0.813-1.469) 0.556 Stent thrombosis 8 (0.8) 11 (2.5) 0.013 2.997 (1.205-7.451) 0.018 Total MACE 87 (9.1) 60 (13.4) 0.006 1.579 (1.135-2.196) 0.007
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.